Skip to content
Versha Banerji, MD, FRCPC

Versha Banerji, MD, FRCPC

Dr. Versha Banerji, MD, FRCPC obtained her MD and residency training in internal medicine and hematology at the University of Manitoba. She then completed a post-doctoral fellowship in translational research at the Harvard Cancer Centre/ Dana-Farber Cancer Institute and Broad Institute of MIT. She is a senior scientist at the CancerCare Manitoba Research Institute, Associate Professor at the University of Manitoba, and a clinician-scientist at CancerCare Manitoba. She co-leads the CLL clinic and is involved in several clinical trials and population-based treatment studies. As co-chair of the CLL research program she manages a multi-disciplinary research team in clinical, fundamental and translational research. Her own laboratory is evaluating mitochondrial bioenergetics and function as a measure of cancer cell metabolism.

With great power comes great responsibility: managing side effects of novel treatments in chronic lymphocytic leukemia (CLL)

The treatment paradigm shift in CLL has uprooted many clinicians’ standard practices. Previously, treatment largely depended on age, organ function and “fitness” based on clinical trials which used CIRS (cumulative illness rating scale) scores1. Today, as a hematologist who mainly treats patients with CLL, treatment strategies are more complex and multi-factorial. Treatments are based on molecular profiling, which aids in the identification of lower-risk patients for time-limited treatment2 options versus higher-risk patients (IGVH unmutated3, del 17p or TP534 ) who benefit from continuous therapies5,6. The highest-risk patients can be identified using a staging system for CLL known as the CLL-International Prognostic Index (CLL-IPI)7-10. However, increased CIRS scores are prognostic for poor outcomes independent of the CLL-IPI11. As a result, selecting the right treatment for the right individual has never been more important, especially in the era of novel therapeutics. This treatment selection decision pathway includes understanding both patient factors and medical factors that may influence patient outcomes. 

Novel time-limited treatment options in Canada at this time include venetoclax and obinutuzumab2 combination therapy for patients who are deemed “unfit” for FCR (fludarabine, cyclophosphamide, rituximab) in the frontline setting and venetoclax and rituximab12 in the relapsed setting. Venetoclax can also be used as monotherapy13 in the relapsed setting (Figure 1). 

Figure 1. Treatment algorithm for CLL; CADTH Reimbursement Review Provisional Funding Algorithm; May 2021

In the front-line setting obinutuzumab is the monoclonal antibody in the VenO regimen. It can cause TLS, infusion related reactions, neutropenia, and febrile neutropenic events2,14-18. Venetoclax, is an oral agent delivered following obinutuzumab administration on Cycle 1 Day 22 continuing through Cycle 2 Day 2818. One of the major challenges in the treatment of CLL with venetoclax involves the assessment of tumour lysis syndrome (TLS) risk (Figure 2). 

Figure 2. Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia; adapted from Fischer et al

Venetoclax is initiated at a starting dose of 20 mg once daily for 7 days and then titrated to a weekly ramp-up schedule of 400 mg over a period of 5 weeks. The TLS monitoring requirements recommend bloodwork 3 days a week to ensure no evidence of TLS after each dose escalation18. Blood chemistry monitoring should be performed for all patients at 6 to 8 hours post-dose, and 24 hours post-dose for the first dose of 20 and 50 mg, and pre-dose at subsequent ramp-up doses. The next dose should not be administered until 24-hour blood chemistry results have been evaluated.

Since the risk of developing TLS is highest when treatment is initiated and the overall tumor mass is highest, debulking may be warranted. Our center will often pre-treat patients with a dose of 10 mg for a week to help reduce the risk of TLS and extend the ramp-up schedule to 6 weeks. The use of pharmacological agents as part of a debulking strategy should be considered in certain scenarios to improve the tolerability and safety of first treatment cycles with chemoimmunotherapy. Some data shows that obinutuzumab reduces the TLS risk from high risk to moderate risk when a debulking strategy is initiated18.The ramp-up can also be shortened in the inpatient setting if required especially in a second line setting when patients are rapidly progressing off a Bruton’s Tyrosine Kinase Inhibitor (BTKi)19 to gain control rapidly. 

A similar approach applies in the relapsed setting. In relapse, rituximab is administered after the venetoclax, in cycle 2 and thus minimal debulking pre-ramp-up occurs. The total duration of rituximab therapy in combination with venetoclax is 6 months, a similar duration with obinutuzumab in the frontline setting. However, the treatment duration of venetoclax is 24 months in relapse setting instead of 12 months as administered with obinutuzumab front line. Other side effects commonly experienced (≥ 20% of any Grade) with the use of venetoclax as monotherapy are neutropenia, diarrhea, nausea, anemia, thrombocytopenia, fatigue, upper respiratory tract infection and cough. The most common (≥ 20%) adverse reactions of any grade reported in patients receiving venetoclax in combination with obinutuzumab were neutropenia, and diarrhea. The most common (≥ 5%) Grade 3/4 reactions in the venetoclax + obinutuzumab patients were neutropenia, anemia, and febrile neutropenia. 

There are a number of simple interventions available to manage adverse events related to venetoclax. The use of granulocyte colony-stimulating factor (G-CSF) in the setting of combination monoclonal anti-CD20 agent + venetoclax has been shown to be helpful especially in the frontline, when depth of response for optimal remission in a short period is the goal. In the past, the concern was that G-CSF use could mask marrow toxicity in combination with chemoimmunotherapy, thereby increasing the risk of MDS or secondary AML 20,21.  Another approach to managing adverse reactions includes holding the venetoclax and dose reductions as shown in trials 2,12. Holding of the monoclonal antibody is not recommended unless there is a clinically significant event such as febrile neutropenia. These time-limited novel options benefit patients by providing them time off therapy2,12. There are fewer side effects related to cardiac and skin toxicities but diarrhea and or constipation may occur. 

Venetoclax administered as monotherapy may also be considered when high risk patients progress on continuous therapy with BTKi or when patients do not tolerate BTKi due to their toxicity profile13. It is important to note that in both the CLL 14 trial and in retrospective reviews of real-world clinical practice, only 80-85% of patients achieved dose escalation to the maximum recommended dose of 400 mg daily22. In some studies, rates of neutropenia with venetoclax monotherapy in the relapsed setting were 47% 22 and in the CLL14  setting it was 53%2. Thrombocytopenia was observed in greater than one-third of cases in both real world evidence and trial settings2, 22. These toxicities were managed by either dose holds or dose reductions2. Febrile neutropenic episodes (FNE) occurred in 10-12% of patients, and may be managed with the use of G-CSF2, 22.

BTK inhibitors have changed the treatment landscape for patients with high-risk CLL. They have been used in salvaging patients in relapse who were initially treated with chemotherapy23. In addition, their widespread uptake in the frontline has spared many patients from treatments that are not efficacious 24-26. Published toxicities 27 associated with BTKi use include off target effects such skin rashes, folliculitis, panniculitis, paronychia due to the on target endothelial growth factor receptor effects, gastrointestinal effects commonly associated with interleukin-2–inducible T-cell kinase (ITKs), and non-thrombocytopenia-associated bleeding due to inhibition of platelet aggregation 28,29. Arthralgias have also been reported in studies and in the real world 23,29,30. It is important for clinicians to be aware that significant variation may exist between rates of adverse effects documented in the initial pivotal studies using BTKi and in a real-world settings. Real-world data has shown differing rates of dose reductions or discontinuation (increased) in the frontline and relapsed settings. Over time cardiac events, including atrial fibrillation, hypertension, ventricular arrythmias and sudden death have been associated with the use of BTKi 29,31 and may be due to off-target effects. A 140 mg dose of ibrutinib (1/3 of the prescribed dose) has been shown to enable 90% BTK inhibition. Although, it is hypothesized that some of the off-target effects of the drug in both blood and lymph nodes contribute to deep and lasting remission. That said, dose reductions or dose holds may also be used to offset these toxicities especially in low risk individuals32,33. RWE studies corroborated this28,34, and clinical trials also reported drug discontinuation as an option for the management of adverse reactions as demonstrated in the ECOG 1912 study 25. However, the risk of sudden death still remained 25,31. The rates of atrial fibrillation for ibrutinib have been reported to be in 10-20% range in both the real world 25,28 and trial settings 24-26. The next generation of BTKi are proving safer than ibrutinib. Where head-to-head data are available, decreased rates of atrial fibrillation and hypertension are observed for acalabrutnib35,36 (rates of 3-4% for all grades for both) and decreased rates of atrial fibrillation (1-3%) and similar rates of hypertension (10-13%) with zanubrutinib 37. Zanubrutinib has been associated with higher rates of neutropenia than ibrutinib, however due to the short period of follow up in clinical trial reporting (12 months), this toxicity profile needs further assessment 37.

Acalabrutinib is most often used in our center due to a decreased side effect profile and minimal risk of sudden death. Our center has rarely reported atrial fibrillation in our acalabrutinib patients however we may also be better at selecting patients for BTKi use. The discontinuation of a BTKi (due the atrial fibrillation) is not recommended in high-risk patients unless medical management of the atrial fibrillation is of concern. If a patient has been initiated on ibrutinib, clinicians may consider challenging the patient with a second-generation BTKi38 before discontinuing this line of therapy. In lower risk individuals whose atrial fibrillation does not resolve and who require therapy, a switch to a BCL-2 inhibitor-based fixed-duration therapy is a viable treatment option. If the patient is low risk and has been on therapy for at least 22 months with ibrutinib, there is also the possibility of stopping treatment until disease relapses requiring re-initiation of treatment25.

Patients on BTKi are at higher risk for developing hypertension. This may occur early or later in the course of therapy. Patients with undiagnosed hypertension should be assessed and co-managed with their primary care physicians. In those patients on established therapy, whose disease is well-controlled and who develop hypertension, dose reduction and engagement with primary care is warranted. Care coordination with cardio-oncology may also be a good resource if available. Second generation BTKi have also been associated with a lower incidence of arthralgias 30 and bleeding but may produce drug-specific side effects such as headaches with acalabrutinib 6,35, which typically present within the first 12 weeks of initiation of therapy29. 

As we look to the future of novel therapies for the treatment and management of CLL, emerging agents such as pirtobrutinib portend a toxicity profile that is similar to current second generation BTKi in both BTKi-naïve and sensitive patients 39,40. Additional studies involving newer BTKi such as nemtabrutinib have the potential for even lower rates of cardiac events which may provide clinicians with further tools in their therapeutic armamentarium to optimize safety and efficacy outcomes for CLL patients.


1 Salvi, F. et al. A manual of guidelines to score the modified cumulative illness rating scale and its validation in acute hospitalized elderly patients. J Am Geriatr Soc 56, 1926-1931, doi:10.1111/j.1532-5415.2008.01935.x (2008).

2 Al-Sawaf, O. et al. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 21, 1188-1200, doi:10.1016/S1470-2045(20)30443-5 (2020).

3 Crombie, J. & Davids, M. S. IGHV mutational status testing in chronic lymphocytic leukemia. Am J Hematol 92, 1393-1397, doi:10.1002/ajh.24808 (2017).

4 Te Raa, G. D. & Kater, A. P. TP53 dysfunction in CLL: Implications for prognosis and treatment. Best Pract Res Clin Haematol 29, 90-99, doi:10.1016/j.beha.2016.08.002 (2016).

5 Byrd, J. C. et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 369, 32-42, doi:10.1056/NEJMoa1215637 (2013).

6 Sharman, J. P. et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet 395, 1278-1291, doi:10.1016/S0140-6736(20)30262-2 (2020).

7 Parikh, S. A. Chronic lymphocytic leukemia treatment algorithm 2018. Blood Cancer J 8, 93, doi:10.1038/s41408-018-0131-2 (2018).

8 International, C. L. L. I. P. I. w. g. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol 17, 779-790, doi:10.1016/S1470-2045(16)30029-8 (2016).

9 Molica, S. et al. The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients. Am J Hematol 91, 1090-1095, doi:10.1002/ajh.24493 (2016).

10 Gentile, M. et al. Validation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patients. Blood 128, 2093-2095, doi:10.1182/blood-2016-07-728261 (2016).

11 Rigolin, G. M. et al. In CLL, comorbidities and the complex karyotype are associated with an inferior outcome independently of CLL-IPI. Blood 129, 3495-3498, doi:10.1182/blood-2017-03-772285 (2017).

12 Kater, A. P. et al. Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study. J Clin Oncol 37, 269-277, doi:10.1200/JCO.18.01580 (2019).

13 Stilgenbauer, S. et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol 17, 768-778, doi:10.1016/S1470-2045(16)30019-5 (2016).

14 Goede, V. et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 370, 1101-1110, doi:10.1056/NEJMoa1313984 (2014).

15 Goede, V. et al. Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study. Leukemia 29, 1602-1604, doi:10.1038/leu.2015.14 (2015).

16 Panovska, A. et al. Real-world data on efficacy and safety of obinutuzumab plus chlorambucil, rituximab plus chlorambucil, and rituximab plus bendamustine in the frontline treatment of chronic lymphocytic leukemia: The GO-CLLEAR Study by the Czech CLL Study Group. Hematol Oncol 38, 509-516, doi:10.1002/hon.2744 (2020).

17 Bourrier, N. et al. Real world risk of infusion reactions and effectiveness of front-line obinutuzumab plus chlorambucil compared with other frontline treatments for chronic lymphocytic leukemia. BMC Cancer 22, 148, doi:10.1186/s12885-022-09256-2 (2022).

18 Fischer, K., Al-Sawaf, O. & Hallek, M. Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2020, 357-362, doi:10.1182/hematology.2020000120 (2020).

19 Koenig, K. L. et al. Safety of venetoclax rapid dose escalation in CLL patients previously treated with B-cell receptor signaling antagonists. Blood Adv 4, 4860-4863, doi:10.1182/bloodadvances.2020002593 (2020).

20 Cooper, J. P. et al. Outcomes of Patients With Therapy-Related MDS After Chemoimmunotherapy for Chronic Lymphocytic Leukemia Compared With Patients With De Novo MDS: A Single-Institution Experience. Clin Lymphoma Myeloma Leuk 19, 390-395, doi:10.1016/j.clml.2019.03.003 (2019).

21 Tambaro, F. P. et al. Outcomes for patients with chronic lymphocytic leukemia and acute leukemia or myelodysplastic syndrome. Leukemia 30, 325-330, doi:10.1038/leu.2015.227 (2016).

22 Mato, A. R. et al. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. Haematologica 103, 1511-1517, doi:10.3324/haematol.2018.193615 (2018).

23 Munir, T. et al. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol 94, 1353-1363, doi:10.1002/ajh.25638 (2019).

24 Woyach, J. A. et al. Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. N Engl J Med 379, 2517-2528, doi:10.1056/NEJMoa1812836 (2018).

25 Shanafelt, T. D. et al. Long-term Outcomes for Ibrutinib-Rituximab and Chemoimmunotherapy in CLL: Updated Results of the E1912 Trial. Blood, doi:10.1182/blood.2021014960 (2022).

26 Shanafelt, T. D. et al. Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. N Engl J Med 381, 432-443, doi:10.1056/NEJMoa1817073 (2019).

27 Lipsky, A. & Lamanna, N. Managing toxicities of Bruton tyrosine kinase inhibitors. Hematology Am Soc Hematol Educ Program 2020, 336-345, doi:10.1182/hematology.2020000118 (2020).

28 Uminski, K. et al. Descriptive analysis of dosing and outcomes for patients with ibrutinib-treated relapsed or refractory chronic lymphocytic leukemia in a Canadian centre. Curr Oncol 26, e610-e617, doi:10.3747/co.26.4957 (2019).

29 O’Brien, S. M. et al. Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice. Front Oncol 11, 720704, doi:10.3389/fonc.2021.720704 (2021).

30 Rhodes, J. M. et al. Ibrutinib-associated Arthralgias/Myalgias in Patients With Chronic Lymphocytic Leukemia: Incidence and Impact on Clinical Outcomes. Clin Lymphoma Myeloma Leuk 20, 438-444 e431, doi:10.1016/j.clml.2020.02.001 (2020).

31 Lampson, B. L. et al. Ventricular arrhythmias and sudden death in patients taking ibrutinib. Blood 129, 2581-2584, doi:10.1182/blood-2016-10-742437 (2017).

32 Bose, P. & Gandhi, V. Recent therapeutic advances in chronic lymphocytic leukemia. F1000Res 6, 1924, doi:10.12688/f1000research.11618.1 (2017).

33 Bose, P., Chen, L. S. & Gandhi, V. Ibrutinib dose and clinical outcome in chronic lymphocytic leukemia – learning from the ‘real world’. Leuk Lymphoma 60, 1603-1605, doi:10.1080/10428194.2019.1571207 (2019).

34 Parikh, S. A. et al. The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice. Cancer Med 9, 3390-3399, doi:10.1002/cam4.2998 (2020).

35 Byrd, J. C. et al. Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial. J Clin Oncol 39, 3441-3452, doi:10.1200/JCO.21.01210 (2021).

36 Brown, J. R. et al. Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients. Haematologica, doi:10.3324/haematol.2021.278901 (2021).

37 Hillmen, P. et al. ALPINE: zanubrutinib versus ibrutinib in relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. Future Oncol 16, 517-523, doi:10.2217/fon-2019-0844 (2020).

38 Awan, F. T. et al. Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib. Blood Adv 3, 1553-1562, doi:10.1182/bloodadvances.2018030007 (2019).

39 Mato, A. R. et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet 397, 892-901, doi:10.1016/S0140-6736(21)00224-5 (2021).

40 Lamanna, N. The emerging role of pirtobrutinib in chronic lymphocytic leukemia. Clin Adv Hematol Oncol 20, 212-214 (2022).